Form 4: Director Sujal Shah Receives Tvardi Therapeutics Options

Director Sujal Shah was granted 6,000 stock options in Tvardi Therapeutics, Inc. as part of a standard equity compensation plan.

Summary

• Director Sujal Shah acquired 6,000 stock options in Tvardi Therapeutics, Inc. (TVRD).
• The options have an exercise price of $2.78 per share.
• The grant date for the transaction was June 9, 2026.
• The options are set to expire on June 8, 2036.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries a neutral sentiment.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• The issuance of new options results in minor potential dilution for existing shareholders.

Risks

• The value of the options is dependent on the future market performance of Tvardi Therapeutics common stock.

Future Outlook

The options vest on the earlier of June 9, 2027, or the date of the next annual meeting of stockholders, contingent upon continuous service.

Industry Context

StockSavvy.ai notes that equity grants to directors are standard corporate governance practices in the biotechnology sector to ensure leadership remains incentivized toward long-term clinical and commercial milestones.

Comparison to Industry Standards

• The grant of stock options to non-employee directors is consistent with standard compensation practices for small-cap biotechnology firms.
• The vesting schedule of one year is typical for director equity awards in the industry.

Stakeholder Impact

• Minor dilution impact on existing shareholders due to the issuance of new equity instruments.

Next Steps

• Vesting of options on June 9, 2027, or the next annual meeting date.

Key Dates

Keywords

Tvardi Therapeutics, TVRD, Form 4, Insider Trading, Stock Options, Director Compensation